Associated Papers
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A et al.
Cancer Science, 2025
Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
Kovach AE et al.
Leukemia & Lymphoma, 2024
39116419 (PubMed )
Supplement: supplement_1.zip › Supplementary_files › Supp_Table_7.xlsx › Suppl_Table_7
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P et al.
Blood Cancer Journal, 2024
38871702 (PubMed )
Supplement: 41408_2024_1078_MOESM1_ESM.pdf
Somatic genetic alterations predict hematological progression in GATA2 deficiency.
Largeaud L et al.
Haematologica, 2023
36727400 (PubMed )
Supplement: 2022_282250_LARGEAUD_TABS4_SUPPL.xlsx › Details
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients.
Nguyen HT et al.
Frontiers in Oncology, 2022
36578946 (PubMed )
Supplement: DataSheet_2.xlsx › Variants_detected_in_FFPE
Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients.
Yuan T et al.
Frontiers in Oncology, 2021
34168983 (PubMed )
Supplement: DataSheet_2.xlsx › Tab_S3.clean_report
Select a paper to view details